What is the Warwick Wellcome Trust Translational Partnership?
Launched in 2020, the Warwick-Wellcome Translational Partnership aims to drive the translation of research into improvements in human health.
The partnership will accelerate the development of new preventative and therapeutic strategies to tackle ill-health locally, nationally and globally. It will help deliver lasting impact, whilst strengthening links with partners in both industry and clinical settings.
What will the Partnership deliver?
The Warwick-Wellcome Trust Translational Partnership will focus on investing in fellowships and projects aimed at exploiting emerging impact in the science of early life, tissue models of human disease and disease control and prevention. Two funding programmes are available to support people and new ideas, whilst developing a translational ecosystem across the University and local NHS trusts. Support for delivery of the Partnership is provided by Research & Impact Services.
Translation Fellowships provide the opportunity for researchers to engage with translational research activities and take forward opportunities. Find out about the fellowships.
Translation and Innovation Grants provide project-focussed pump priming awards to overcome specific barriers and/or directed towards later stage projects that need support to move to the next technology readiness level. Find out about the grants.
Breaking Translational Barriers Awards, smaller awards of up to £10,000, are available to access bespoke external expertise and advice on the potential of the idea or technology and overcome well-defined barriers, for example engaging end users and networks, commissioning market research analyses and exploring routes to market to progress their research along the translational pipeline. The Breaking translational barriers awards will not fund Warwick staff time.Find out about current Breaking Translational Barriers awards.
What funding is currently available?
Warwick has recently secured an extension to the Partnership and is seeking new applications for Translational Fellowship Awards.
This "innovative and very well organised" event brought together 70 attendees from local hospital trusts, regional universities, industry and organisations such as the UK Health Security Agency and LifeArc for a free-form and highly collaborative day designed to spark new collaborations. Expert guest speakers included Dr Tim Hammonds (VP Drug Discovery, Locki Therapeutics Limited) and Dr Laura Lane (Principal, Advent Life Sciences), who were interviewed in Q&A style sessions with questions posed from the delegates. Sessions on the day, aided by the Centre for Facilitation, were aimed at getting people to think about translational barriers to their own work and to discuss broader challenges facing universities, industry and hospitals when it comes to translation.
Smaller awards of up to £10,000, are available to access bespoke external expertise and advice on the potential of the idea or technology and overcome well-defined barriers, for example engaging end-users and networks, commissioning market research analyses and exploring routes to market to progress their research along the translational pipeline.